Pharvaris

Exited

Pharvaris is a clinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients.

Total raised

€68M

€67,504,400

Funding rounds

Investors

distinct backers

Active since

2020-11

latest 2020-11

Funding by year

EUR raised per year

1 rounds

Date	Stage	Amount	Investors
2020-11-18	Series C	€68M	General Atlantic,Viking Global Investors	View deal →

Type

ipo

Date

Jul 2025

Value

€172M

Acquiror

—

same sector or country